Literature DB >> 15502817

Antidote-mediated control of an anticoagulant aptamer in vivo.

Christopher P Rusconi1, Joseph D Roberts, George A Pitoc, Shahid M Nimjee, Rebekah R White, George Quick, Elizabeth Scardino, William P Fay, Bruce A Sullenger.   

Abstract

Patient safety and treatment outcome could be improved if physicians could rapidly control the activity of therapeutic agents in their patients. Antidote control is the safest way to regulate drug activity, because unlike rapidly clearing drugs, control of the drug activity is independent of underlying patient physiology and co-morbidities. Until recently, however, there was no general method to discover antidote-controlled drugs. Here we demonstrate that the activity and side effects of a specific class of drugs, called aptamers, can be controlled by matched antidotes in vivo. The drug, an anticoagulant aptamer, systemically induces anticoagulation in pigs and inhibits thrombosis in murine models. The antidote rapidly reverses anticoagulation engendered by the drug, and prevents drug-induced bleeding in surgically challenged animals. These results demonstrate that rationally designed drug-antidote pairs can be generated to provide control over drug activities in animals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15502817     DOI: 10.1038/nbt1023

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  79 in total

1.  A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage.

Authors:  Charlene M Blake; Haichen Wang; Daniel T Laskowitz; Bruce A Sullenger
Journal:  Oligonucleotides       Date:  2010-12-13

Review 2.  Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.

Authors:  Thomas J Povsic; Bruce A Sullenger; Steven L Zelenkofske; Christopher P Rusconi; Richard C Becker
Journal:  J Cardiovasc Transl Res       Date:  2010-11-16       Impact factor: 4.132

Review 3.  Modulation of the Coagulation Cascade Using Aptamers.

Authors:  Rebecca S Woodruff; Bruce A Sullenger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-08-27       Impact factor: 8.311

4.  A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.

Authors:  K-A Steen Burrell; J Layzer; B A Sullenger
Journal:  J Thromb Haemost       Date:  2017-08-02       Impact factor: 5.824

Review 5.  Aptamers: multifunctional molecules for biomedical research.

Authors:  Jayeeta Banerjee; Marit Nilsen-Hamilton
Journal:  J Mol Med (Berl)       Date:  2013-09-18       Impact factor: 4.599

6.  Aptamer photoregulation in vivo.

Authors:  Lele Li; Rong Tong; Hunghao Chu; Weiping Wang; Robert Langer; Daniel S Kohane
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

7.  Reversal of siRNA-mediated gene silencing in vivo.

Authors:  Ivan Zlatev; Adam Castoreno; Christopher R Brown; June Qin; Scott Waldron; Mark K Schlegel; Rohan Degaonkar; Svetlana Shulga-Morskaya; Huilei Xu; Swati Gupta; Shigeo Matsuda; Akin Akinc; Kallanthottathil G Rajeev; Muthiah Manoharan; Martin A Maier; Vasant Jadhav
Journal:  Nat Biotechnol       Date:  2018-05-14       Impact factor: 54.908

Review 8.  Programmable hydrogels.

Authors:  Yong Wang
Journal:  Biomaterials       Date:  2018-03-05       Impact factor: 12.479

Review 9.  Triggers, targets and treatments for thrombosis.

Authors:  Nigel Mackman
Journal:  Nature       Date:  2008-02-21       Impact factor: 49.962

10.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.